To investigate the potential of CD133 as a molecular biomarker of melanoma progression and disease recurrence, we assessed CD133 mRNA transcript levels by qRT-PCR in low passage (<20) primary cell lines established from fresh tissues of patients with either poor outcome and short overall survival, or from patients with good outcome and long overall survival status. This evidence concerns the gene PROM1 and melanoma.